Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02500407
Registration number
NCT02500407
Ethics application status
Date submitted
14/07/2015
Date registered
16/07/2015
Date last updated
3/05/2024
Titles & IDs
Public title
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Query!
Scientific title
An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Query!
Secondary ID [1]
0
0
GO29781
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lymphocytic Leukemia, Chronic
0
0
Query!
Lymphoma, Non Hodgkin
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BTCT4465A (Mosunetuzumab) IV
Treatment: Drugs - Atezolizumab
Treatment: Drugs - BTCT4465A (Mosunetuzumab) SC
Experimental: Dose Escalation - Participants will receive BTCT4465A (Mosunetuzumab) via intravenous (IV) infusion or subcutaneous (SC) injection as a single-agent or in combination with atezolizumab. Dose escalation will be guided by the observed incidence of DLTs at each dose level.
Experimental: Dose Expansion - Participants will receive BTCT4465A (Mosunetuzumab) as a single-agent or in combination with atezolizumab.
Treatment: Drugs: BTCT4465A (Mosunetuzumab) IV
Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.
Treatment: Drugs: Atezolizumab
Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
Treatment: Drugs: BTCT4465A (Mosunetuzumab) SC
Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Maximum Tolerated Dose (MTD) of BTCT4465A (Mosunetuzumab)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
BTCT4465A (Mosunetuzumab) single agent: Cycle 1; BTCT4465A (Mosunetuzumab) in combination with atezolizumab: during the first cycle that BTCT4465A (Mosunetuzumab) and atezolizumab are administered concurrently (cycle length = 21 days)
Query!
Primary outcome [2]
0
0
Percentage of Participants With Adverse Events
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Cycle 1 Day 1 until 90 days after the last infusion (cycle length = 21 days; up to approximately 14 months)
Query!
Primary outcome [3]
0
0
BTCT4465A (Mosunetuzumab) Serum Concentration
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Baseline up to 30 days after the last infusion of BTCT4465A (Mosunetuzumab) (up to approximately 12 months)
Query!
Primary outcome [4]
0
0
Atezolizumab Serum Concentration
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline up to 30 days after the last infusion of BTCT4465A (Mosunetuzumab) (up to approximately 12 months)
Query!
Primary outcome [5]
0
0
Percentage of Participants with Complete Response as Assessed Using Standard Criteria for NHL
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline up to approximately 4 years (assessed at screening and then every 3 months until disease progression, start of new anti-cancer therapy, or withdrawal)
Query!
Secondary outcome [1]
0
0
Duration of Response as Assessed Using Standard Criteria for NHL
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline up to approximately 4 years (assessed at screening and then every 3 months until disease progression, start of new anti-cancer therapy, or withdrawal)
Query!
Secondary outcome [2]
0
0
Progression-Free Survival (PFS) as Assessed Using Standard Criteria for NHL
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline up to approximately 4 years (assessed at screening and then every 3 months until disease progression, start of new anti-cancer therapy, withdrawal, or death from any cause)
Query!
Secondary outcome [3]
0
0
Overall Survival
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Baseline until death from any cause (up to approximately 4 years)
Query!
Secondary outcome [4]
0
0
European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) Scores to Assess Health-Related Quality of Life (HRQoL)
Query!
Assessment method [4]
0
0
The Functional Assessment of Cancer Therapy-Lymphoma (FACT-lym) Subscale, and the EuroQol 5 Dimension-5 Level (EQ-5D-5L) Questionnaire scores will also be used to assess HRQoL
Query!
Timepoint [4]
0
0
Baseline until disease progression, start of new anti-cancer therapy, or withdrawal (up to approximately 4 years).
Query!
Secondary outcome [5]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline up to approximately 4 years (assessed at screening and then every 3 months until disease progression, start of new anti-cancer therapy, or withdrawal)
Query!
Eligibility
Key inclusion criteria
Key
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- B-cell hematologic malignancies expected to express the cluster of differentiation 20
(CD20) antigen who have relapsed after or failed to respond to at least one prior
treatment regimen and for whom there is no available therapy expected to improve
survival
- Adequate hepatic, hematologic, and renal function
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Pregnant or lactating women
- Monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate, chemotherapy, or
other investigational anti-cancer agent within 4 weeks prior to study drug
- Treatment with radiotherapy within 2 weeks prior to the first BTCT4465A
(Mosunetuzumab) administration
- Systemic immunosuppressive medication within 2 weeks prior to study drug
- Autologous stem cell transplantation (SCT) within 100 days prior to study drug, or any
prior allogeneic SCT or solid organ transplantation
- Autoimmune disease with the exception of controlled/treated hypothyroidism,
disease-related immune thrombocytopenic purpura, or hemolytic anemia
- History of central nervous system (CNS) lymphoma or other CNS disease
- Significant cardiovascular or pulmonary disease
- Hepatitis B or C or human immunodeficiency virus (HIV)
- Receipt of a live attenuated vaccine within 4 weeks prior to study drug
- Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 30 days
before first BTCT4465A (Mosunetuzumab) administration
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/09/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
15/11/2025
Query!
Actual
Query!
Sample size
Target
836
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
St Vincent's Hospital Sydney - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Wollongong Hospital; Cancer Care Centre - Wollongong
Query!
Recruitment hospital [3]
0
0
Icon Cancer Care South Brisbane - South Brisbane
Query!
Recruitment hospital [4]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [5]
0
0
Royal Adelaide Hospital; Haematology Clinical Trials - Adelaide
Query!
Recruitment hospital [6]
0
0
St. Vincent's Hospital Melbourne - Fitzroy
Query!
Recruitment hospital [7]
0
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [8]
0
0
Monash Health Clinical Trial Pharmacy department - Clayton
Query!
Recruitment hospital [9]
0
0
The Alfred - Melbourne
Query!
Recruitment hospital [10]
0
0
Linear Clinical Research Limited - Nedlands
Query!
Recruitment hospital [11]
0
0
The Perth Blood Institute - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [5]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [6]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [7]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [8]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [9]
0
0
3124 - Melbourne
Query!
Recruitment postcode(s) [10]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New Jersey
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Oregon
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Tennessee
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Washington
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
British Columbia
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Ontario
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Quebec
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Bremen
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Dortmund
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Heidelberg
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Koln
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Mainz
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
München
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Münster
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Würzburg
Query!
Country [23]
0
0
Korea, Republic of
Query!
State/province [23]
0
0
Seoul
Query!
Country [24]
0
0
Spain
Query!
State/province [24]
0
0
Navarra
Query!
Country [25]
0
0
Spain
Query!
State/province [25]
0
0
Barcelona
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
Madrid
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Salamanca
Query!
Country [28]
0
0
United Kingdom
Query!
State/province [28]
0
0
London
Query!
Country [29]
0
0
United Kingdom
Query!
State/province [29]
0
0
Manchester
Query!
Country [30]
0
0
United Kingdom
Query!
State/province [30]
0
0
Sutton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Genentech, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a
single agent and in combination with atezolizumab in participants with relapsed or refractory
B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage
where participants will be enrolled into indication-specific cohorts.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02500407
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02500407
Download to PDF